搜索临床试验以：PD-1/PDL-1 表达的评估。
总计10408个结果
-
Instituto Nacional de Cancerologia de Mexico未知
-
University of Colorado, DenverNational Cancer Institute (NCI); Cancer League of Colorado撤销
-
The First Affiliated Hospital of Guangdong Pharmaceutical...University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co., Ltd.未知
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.尚未招聘
-
Shanghai Cell Therapy Research Institute未知
-
Tongji University招聘中
-
Shanghai Cell Therapy Research Institute未知
-
Tongji HospitalNational Natural Science Foundation of China招聘中
-
Centre Leon BerardNETRIS Pharma招聘中
-
Shanghai Junshi Bioscience Co., Ltd.主动，不招人
-
The First Affiliated Hospital of Guangdong Pharmaceutical...Guangzhou Anjie Biomedical Technology Co., Ltd.未知
-
Pfizer主动，不招人肾细胞癌 | 胃癌 | 胰腺癌 | 食道癌 | 卵巢癌 | 头颈部鳞状细胞癌 | 胆管癌 | 子宫内膜癌 | 尿路上皮癌 | 肺鳞状细胞癌 | 黑色素瘤癌症美国, 台湾, 大韩民国, 澳大利亚, 斯洛伐克
-
Mahmoud Ramadan mohamed Elkazzaz尚未招聘
-
Second Affiliated Hospital, School of Medicine,...Westlake Therapeutics招聘中
-
Beijing YouAn HospitalBeijing Gene Key Life Technology Co., Ltd.招聘中
-
Peking University First HospitalYiZhou International Cancer Hospital未知免疫疗法 | 质子治疗
-
Second Affiliated Hospital of Soochow UniversitySciClone Pharmaceuticals招聘中
-
Second Affiliated Hospital of Soochow University尚未招聘
-
Chinese PLA General HospitalLinkDoc Technology (Beijing) Co. Ltd.未知
-
Tianjin Medical University Cancer Institute and...Jiangsu HengRui Medicine Co., Ltd.完全的
-
University Hospital, Bordeaux招聘中在使用 PD1/PDL1 ICIs + VEGFR-酪氨酸激酶抑制剂治疗 12 个月时有客观反应的 mRCC 患者中只有一个不良预后因素的 IMDC 良好或中等风险的治疗暂停与治疗继续 (SPICI)转移性肾细胞癌 | 每个 IMDC 评分的良好或只有一个不良预后因素中等风险法国
-
Sixth Affiliated Hospital, Sun Yat-sen University招聘中
-
Shanghai Zhongshan HospitalJining Medical University; Cancer Hospital of Guangxi Medical University主动，不招人
-
Peking University First HospitalYiZhou International Cancer Hospital未知肿瘤转移 | 免疫疗法 | 质子治疗